Latest

Global Health: Fighting the Good Fight

Pharm Exec details the latest approaches to combating disease and health crises on a global scale—including industry perspectives from those involved on the front lines.

Global Health: Partnerships Hold the Key

Amid a widening net of health threats worldwide, alliances forged in research and response may be more critical than ever to stem the tide.

Global Health: Messages of Hope

Figuring out the right formula to address global health—for the better.

PharmExec Videos

New & Noteworthy

Access and Reimbursement for Adoptive T-Cell Transfer Drugs

Groundbreaking treatment approaches call for innovative commercialization strategies.

Fulfilling the Vision of Science: AstraZeneca's Ruud Dobber

Drawing from his research roots and the leadership lessons gained in melding business and culture in geographies across the globe, Ruud Dobber is busy steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.

Lessons Learned from the Multichannel Shakeout

Innovation by itself won't solve the complex multichannel challenges pharmas face. Jeff Greene reports.

The Power of MSL Authenticity

Paul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.

Taking Command of Strategy Execution

Mark Bouch, Stephen Bungay, and David Roblin outline how the technique of "mission command", a military approach to setting direction and executing strategy in the pharmaceutical industry, has developed over the last ten years.

Sales & Marketing

New Targets for the Osteoporosis Market

Bagrat Lalayan presents an overview of osteoporosis treatment market and offers vision for future business strategies.

The Power of MSL Authenticity

Paul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.

Multidisciplinary Care Teams: Challenge or Opportunity?

Abigail Bernardi explains how a better understanding of connections among practitioners on care teams helps sales reps build relationships while benefitting a company’s marketing efforts.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

First Foray into Digital Adherence

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

A Year of Transformation for Science & Medicine

In 2017, patients gained access to the first gene therapies and more orphan and breakthrough drugs.

Will Europe Turn a Corner in Personalized Medicine?

New action plan urges tighter alignment of public health policy with the development of targeted therapies.

No Cancer Left Behind: Drug Combination with Device Aims to Improve Cancer Outcomes [SPONSORED]

This Q&A with Lumicell CEO Kelly Londy discusses new drug-device technologies in development for a range of cancers, beginning with breast cancer in the most advanced clinical studies.

News Update

Johnson & Johnson, Sanofi Top the 2017 Good Pharma Scorecard

The 2017 GPS ranking evaluates clinical trial registration, results reporting, clinical study report synopsis sharing, and journal article publication rates for new drugs approved by the Food and Drug Administration in 2014 that were sponsored by large drug companies.

Compliance Top of Mind

There is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry. The articles from Pharmaceutical Executive provide a look at the latest in compliance for marketing, labeling, and export control, as well as offer tips to stay compliant in the coming years.
 

Read More.

Interviews

Abbott: Why Branded Generics Matter

Andrew Lane, EVP, Established Pharmaceuticals at Abbott, tells Pharm Exec how understanding emerging market dynamics can explain why branded generic medicines are important.

Rewarding Creative Thinking in Oncology: The Astellas C3 Prize

Mark Reisenauer, SVP, Oncology Business Unit at Astellas, tells PharmExec about the development and objectives of the Astellas Oncology C3 Prize.

Driving Decisions with Data: Sundeep Bhan, CEO, Prognos

Prognos CEO Sundeep Bhan talks about how the company’s unique offering will reach beyond life sciences as the long-promised benefits of AI become reality.

Regulatory

New Report Stresses Importance of Affordable Drugs

Experts slam drug prices and endorse government price negotiations and curbs on drug advertising.

Manufacturers and Trading Partners Struggle to Meet Drug Tracking Requirements

Halfway through the process for establishing a national electronic drug tracking system, there’s concern among pharma companies, distributors, and pharmacists about meeting the 2023 deadline

Sponsors Work with FDA to Streamline Combo Product Development and Oversight

Jill Wechsler discusses the hot topic of how FDA should oversee combination products that incorporate a digital health component.

From the Editor

First Foray into Digital Adherence

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

No Overnight Successes

Our annual look at the drug industry's pipeline—the progress and the setbacks—puts my thoughts on those people driving new science behind the scenes in pharmaceutical research.

lorem ipsum